The treatment window for endovascular thrombectomy has been extended from 6 to 24 hours within the onset of a stroke in the new stroke guidelines, expanding the number of patients eligible for thrombectomy. However, experts said this does not mean time no longer matters in thrombectomy.
Despite guidelines advocating stroke risk factor assessment following retinal infarction (stroke of the eye), adherence to the guidelines within 90 days of infarct was poor among elderly patients, leading to a potentially elevated risk of stroke, according to a study presented at the recent International Stroke Conference 2018 (ISC 2018) in Los Angeles, California, US.
The use of a ticagrelor/aspirin combination was more successful than a clopidogrel/aspirin combination in reducing the rate of high on-treatment platelet reactivity (HOPR) in patients with a recent minor stroke or transient ischaemic attack (TIA), according to results of the PRINCE* trial conducted in China.
Combining the anticoagulant rivaroxaban with aspirin reduces the risk of ischaemic stroke by almost half without a significant increase in the risk of intracerebral haemorrhage (ICH) or haemorrhagic transformation compared with aspirin alone in patients with stable coronary artery disease (CAD), according to new data from the COMPASS* study presented at ISC 2018.
The use of tenecteplase may be a suitable alternative to alteplase prior to endovascular thrombectomy in patients with a large vessel ischaemic stroke, according to results of the EXTEND-IA TNK* study.
A combination of the cholesterol-lowering drug rosuvastatin and blood pressure-lowering drugs candesartan and hydrochlorothiazide led to a significant 44 percent reduction in the risk of first strokes among individuals with an intermediate risk of cardiovascular (CV) disease, results from the HOPE-3* study showed.
Presence of fluid sacs in the kidneys may be indicative of an increased risk of stroke, suggest preliminary data from a study presented at the International Stroke Conference (ISC) 2018 in Los Angeles, California, US.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Nonvitamin K antagonist oral anticoagulants (NOACs) appear to confer more clinical benefits to elderly patients with atrial fibrillation (AF) than vitamin K antagonist anticoagulants (VKAs), suggests a study, adding that this is primarily driven by the lower rates of major bleeding.
Associate Professor Ng Lee Ching, Director of the Environmental Health Institute (EHI) at the National Environment Agency (NEA), Singapore, speaks about the role of primary care physicians and government agencies in preventing dengue epidemics.
In patients with atrial fibrillation (AF) naïve to oral anticoagulants (OACs), standard-dose nonvitamin K antagonist OACs (NOACs) provides better survival benefits than warfarin, a recent meta-analysis has shown.